Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK3486 for Sedation in ICU Patients
NCT04147416Phase 2Completed
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Nov 2019
- Primary completion
- May 2020
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cipepofol in sedation (2 arms), sponsored by Sichuan Haisco Pharmaceutical Co., Ltd. Primary endpoint: Mean time to sedation at Day 1. Started Nov 2019; status: completed.
02
Drugs
cipepofol
03
Conditions
sedation
Beyond the preview
Go deeper on NCT04147416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147416.